Mehdi Brahmi
A5078267188- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
- Testicular diseases and treatments
- Ovarian cancer diagnosis and treatment
- Cardiac tumors and thrombi
- Neurofibromatosis and Schwannoma Cases
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Tuberous Sclerosis Complex Research
- Cancer Genomics and Diagnostics
- Bone Tumor Diagnosis and Treatments
- Soft tissue tumor case studies
- Musculoskeletal synovial abnormalities and treatments
- Soft tissue tumors and treatment
- Colorectal and Anal Carcinomas
- Histiocytic Disorders and Treatments
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Gastrointestinal disorders and treatments
- Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Gastric Cancer Management and Outcomes
Centre Léon Bérard
2016-2025
Université Claude Bernard Lyon 1
2017-2025
Centre de Recherche en Cancérologie de Lyon
2014-2024
Centre National de la Recherche Scientifique
2014-2024
Inserm
2014-2024
Novartis (France)
2023
Roche (Switzerland)
2023
Institute Cancer De La Loire Lucien Neuwirth
2023
Cancer Research Center
2022
UniCancer Group
2020
NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome patients. Since 2010, presentation an MDTB and expert pathological review are mandatory for patients nationwide. In present work, impact surgery in center on survival investigated using this national registry.
We investigated the impact of implementation a network reference centers for sarcomas (NETSARC) on care and survival sarcoma patients in France since 2010.
Abstract Purpose: Perivascular epitheliod cell tumors (PEComas) are rare mesenchymal neoplasms for which the role of systemic treatments is not established as there no published prospective clinical trials or sufficiently large retrospective case series. The aim this study to clarify activity conventional chemotherapy and biological agents in advanced/metastatic PEComas. Experimental Design: This was an observational, retrospective, international that included patients with PEComa treated...
Primary or secondary mutations in
Abstract Many neoplasms remain unclassified after histopathological examination, which requires further molecular analysis. To this regard, mesenchymal are particularly challenging due to the combination of their rarity and large number subtypes, many entities still lack robust diagnostic hallmarks. RNA transcriptomic profiles have proven be a reliable basis for classification previously tumors notably neoplasms. Using exome‐based capture sequencing on more than 5000 samples archival...
Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary
<h3>Importance</h3> Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well the potential to respond new targeted drugs. Little known on activity of anthracycline-based regimens, gemcitabine-based pazopanib in this disease. <h3>Objective</h3> To report patients advanced ES. <h3>Design, Setting, Participants</h3> Seventeen reference centers Europe, United States, Japan contributed data retrospective analysis...
Abstract Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated long term effects of IM in TGCT. We conducted an international multi-institutional retrospective assess activity IM: data was collected anonymously from individual...
This study aimed to review the activity of cytotoxic chemotherapy in patients with inflammatory myofibroblastic tumors (IMTs) treated at nine European sarcoma reference centers.Patients any age, histologically proven IMT, anthracycline-based methotrexate plus/minus vinorelbine/vinblastine (MTX-V) or other chemotherapeutic regimens between 1996 and 2018 were retrospectively reviewed. Diagnosis was confirmed local level by an expert pathologist. Response assessed investigators RECIST v1.1....
•This is the largest reported series of advanced CCS patients treated with systemic therapy.•The activity sarcoma-type therapy poor and modest responses were seen only sunitinib.•Effective therapies are needed to improve outcomes for this ultra-rare sarcoma type. BackgroundClear cell (CCS) a translocated aggressive malignancy high incidence metastases prognosis. There few studies describing in CCS. We report multi-institutional retrospective study within World Sarcoma Network (WSN).Materials...
A NATIONWIDE STUDY: Epithelioid hemangioendothelioma (EHE) is an ultrarare sarcoma whose natural history and treatment not well defined. We report on the presentation outcome of 267 patients with EHE in NETSARC+ network since 2010 France.NETSARC (netsarc.org) a 26 reference centres specialised multidisciplinary tumour boards (MDTB), funded by French National Cancer Institute (NCI), Institut du (INCA). Since 2010, to MDTB second pathological review are mandatory for patients. Patients'...
Background Malignant peripheral nerve sheath tumors (MPNST) are one of the most frequent causes death in patients with neurofibromatosis type 1 (NF1). Early detection is crucial because complete surgical resection only curative treatment. It has been previously reported that an 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) image a T/L (Tumor/Liver) SUVmax ratio > 1.5 provides high negative predictive value; however, it not specific enough to make...
Aggressive angiomyxoma (AA) is a rare, locally aggressive tumor usually arising from pelvis or perineum, with high local-recurrence rate after complete surgery. Anecdotal responses to hormone therapy have been reported. In the present study we aimed at studying surgical treatment outcomes and sensitivity of AA.We conducted multicenter, international retrospective effort including patients AA treated three European referral centers (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy...
Soft tissue sarcomas are a group of rare and aggressive connective neoplasms for which curative therapeutic opportunities limited in advanced phase. Clinical trials assessing immunotherapy these tumors have so far reported efficacy. The objective this study is to provide description the immunologic landscape guide next clinical diseases. gene expression profile 93 immune checkpoint (ICP) membrane markers (MM) cells was analyzed series 253 soft sarcoma (synovial sarcoma, myxoid liposarcoma,...